Study summary
Upadacitinib regrew most scalp hair in about half of people
55.0%reached 80% or more scalp coverage on 30 mg, vs 1.5% with placebo
What was tested
Upadacitinib, a JAK1-blocking pill, at 15 or 30 mg against placebo in two replicate phase 3 trials for severe alopecia areata in adults and adolescents.
What they found
- At 24 weeks, 45.2% (15 mg) and 55.0% (30 mg) had 80% or more scalp hair, vs 1.5% with placebo (UP-AA1).
- UP-AA2 showed similar results (44.6% and 54.3% vs 3.4%).
What it means
Likely to become the fourth approved JAK pill for alopecia areata.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.